Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland.
Saved in:
| Title: | Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland. |
|---|---|
| Authors: | Bhadhuri A; Institute of Pharmaceutical Medicine (ECPM), University of Basel, Klingelbergstrasse 61, CH-4056, Basel, Switzerland. Arjun.bhadhuri@unibas.ch., Dröschel D; Institute of Pharmaceutical Medicine (ECPM), University of Basel, Klingelbergstrasse 61, CH-4056, Basel, Switzerland., Guldimann M; Institute of Pharmaceutical Medicine (ECPM), University of Basel, Klingelbergstrasse 61, CH-4056, Basel, Switzerland., Jetschgo C; Novartis Pharma Schweiz AG, Rotkreuz, ZG, Switzerland., Banhazi J; Novartis Pharma AG, Basel, Switzerland., Schwenkglenks M; Institute of Pharmaceutical Medicine (ECPM), University of Basel, Klingelbergstrasse 61, CH-4056, Basel, Switzerland., Sutherland CS; Institute of Pharmaceutical Medicine (ECPM), University of Basel, Klingelbergstrasse 61, CH-4056, Basel, Switzerland. |
| Source: | BMC health services research [BMC Health Serv Res] 2022 Jun 28; Vol. 22 (1), pp. 837. Date of Electronic Publication: 2022 Jun 28. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101088677 Publication Model: Electronic Cited Medium: Internet ISSN: 1472-6963 (Electronic) Linking ISSN: 14726963 NLM ISO Abbreviation: BMC Health Serv Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1472-6963 |
|---|---|
| DOI: | 10.1186/s12913-022-08211-y |
